Climb Bio, Inc. Common Stock
$14.31
$0.25 (+1.78%)
$13.92Day Range$14.32
Key Statistics
Market Cap
$807.55M
Shares Outstanding
57.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 10, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$14.15
Day High
$14.32
Day Low
$13.92
Volume
682.6K
VWAP
$14.18
Prev Close
$14.06
Transactions
--
Acc. Volume
--
About Climb Bio, Inc. Common Stock
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
PHARMACEUTICAL PREPARATIONSSIC 283429 employees20 WILLIAM STREET, WELLESLEY HILLS, MA, 024811-866-857-2596IPO Aug 10, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001768446
- Composite FIGI
- BBG00ZNKL0K6
- Share Class FIGI
- BBG00ZNKL0L5
- Ticker Root
- CLYM
- SIC Code
- 2834
About Climb Bio, Inc. Common Stock (CLYM) Stock
Climb Bio, Inc. Common Stock (CLYM) closed the 2026-09-18 session at $14.31, up 1.78% versus the previous close (+0.25). The stock opened at $14.15 and traded between $13.92 and $14.32 during that session. Session trading volume was 683K shares. The volume-weighted average price (VWAP) is $14.18.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Climb Bio, Inc. Common Stock has a market capitalization of $807.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. CLYM is listed on the XNAS exchange. The company employs approximately 29 people. Climb Bio, Inc. Common Stock is headquartered in WELLESLEY HILLS, MA. The recorded listing date is 2021-08-10.
On this page you can find market CLYM stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.